We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
European Commission Approves Regeneron's Diabetic Macular Edema Drug
News

European Commission Approves Regeneron's Diabetic Macular Edema Drug

European Commission Approves Regeneron's Diabetic Macular Edema Drug
News

European Commission Approves Regeneron's Diabetic Macular Edema Drug

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "European Commission Approves Regeneron's Diabetic Macular Edema Drug"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

"DME is the leading cause of vision loss in working-age adults in much of the developed world, and we believe EYLEA will be an important new treatment option for these patients," said George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories. "We are pleased that EYLEA is now approved in both the U.S. and the EU for three important ophthalmic indications." 

EYLEA was approved in the United States for the treatment of wet Age-related Macular Degeneration (AMD) in 2011, for the treatment of Macular Edema following Central Retinal Vein Occlusion (CRVO) in 2012, and for DME in July 2014. EYLEA has also been approved in the EU and other countries for use in wet AMD and Macular Edema following CRVO. Regulatory submissions have also been made in Japan, Asia Pacific, and Latin America for the treatment of DME. In Japan, EYLEA has been additionally submitted for approval to regulators for the treatment of choroidal neovascularization secondary to pathologic myopia (mCNV). A regulatory submission has been made in the U.S. and the EU for EYLEA for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO). 

Bayer Healthcare plans to launch EYLEA in DME in the EU this quarter. 

Advertisement